Safety and Biodistribution Evaluation in CNGB3-Deficient Mice of rAAV2tYF-PR1.7-hCNGB3,a Recombinant AAV Vector for Treatment of Achromatopsia

Abstract

Applied Genetic Technologies Corporation (AGTC) is developing rAAV2tYF-PR1.7-hCNGB3, a recombinant adeno-associated virus (rAAV) vector expressing the human CNGB3 gene, for treatment of achromatopsia, an inherited retinal disorder characterized by markedly reduced visual acuity, extreme light sensitivity, and absence of color discrimination. We report here results of a study evaluating safety and biodistribution of rAAV2tYF-PR1.7-hCNGB3 in CNGB3-deficient mice. Three groups of animals (n = 35 males and 35 females per group) received a subretinal injection in one eye of 1 μl containing either vehicle or rAAV2tYF-PR1.7-hCNGB3 at one of two dose concentrations (1 × 10¹² or 4.2 × 10¹² vg/ml) and were euthanized 4 or 13 weeks later. There were no test-article-related changes in clinical observations, body weights, food consumption, ocular examinations, clinical pathology parameters, organ weights, or macroscopic observations at necropsy. Cone-mediated electroretinography (ERG) responses were detected after vector administration in the treated eyes in 90% of animals in the higher dose group and 31% of animals in the lower dose group. Rod-mediated ERG responses were reduced in the treated eye for all groups, with the greatest reduction in males given the higher dose of vector, but returned to normal by the end of the study. Microscopic pathology results demonstrated minimal mononuclear cell infiltrates in the retina and vitreous of some animals at the interim euthanasia and in the vitreous of some animals at the terminal euthanasia. Serum anti-AAV antibodies developed in most vector-injected animals. No animals developed antibodies to hCNGB3. Biodistribution studies demonstrated high levels of vector DNA in vector-injected eyes but little or no vector DNA in nonocular tissue. These results support the use of rAAV2tYF-PR1.7-hCNGB3 in clinical studies in patients with achromatopsia caused by CNGB3 mutations.

Get full access to this article

View all access options for this article.

References

Kohl

, Jagle

, Sharpe

, et al. Achromatopsia. In: Gene Reviews. (University of Washington, Seattle, WA). www.ncbi.nlm.nih.gov/bookshelf/br.fcgi?book=gene&part=achm; updated October 23, 2006.

Futterman

. Understanding and Coping with Achromatopsia, 2nd edition. A Publication for The Achromatopsia Network. (Berkley, CA). 2004; www.achromat.org/

Kohl

, Varsanyi

, Antunes

, et al. CNGB3 mutations account for 50% of all cases with autosomal recessive achromatopsia. Eur J Hum Genet, 2005; 13:302–308.

Wissinger

, Gamer

, Jagle

, et al. CNGA3 mutations in hereditary cone photoreceptor disorders. Am J Hum Genet, 2001; 69:722–737.

Kohl

, Baumann

, Rosenberg

, et al. Mutations in the cone photoreceptor G-protein alpha-subunit gene GNAT2 in patients with achromatopsia. Am J Hum Genet, 2002; 71:422–425.

Kohl

, Coppieters

, Meire

, et al. A nonsense mutation in PDE6H causes autosomal-recessive incomplete achromatopsia. Am J Hum Genet, 2012; 91:527–532.

Kohl

, Zobor

, Chiang

, et al. Mutations in the unfolded protein response regulator ATF6 cause the cone dysfunction disorder achromatopsia. Nat Genet, 2015; 47:757–765.

Chang

, Grau

, Dangel

, et al. A homologous genetic basis of the murine cpfl1 mutant and human achromatopsia linked to mutations in the PDE6C gene. Proc Natl Acad Sci U S A, 2009; 106:19581–19586.

Thiadens

, Slingerland

, Roosing

, et al. Genetic etiology and clinical consequences of complete and incomplete achromatopsia. Ophthalmology, 2009; 116:1984–1989.

10.

Sidjanin

, Lowe

, McElwee

, et al. Canine CNGB3 mutations establish cone degeneration as orthologous to the human achromatopsia locus ACHM3. Hum Mol Genet, 2002; 11:1823–1833.

11.

Ding

, Harry

, Umino

, et al. Impaired cone function and cone degeneration resulting from CNGB3 deficiency: down-regulation of CNGA3 biosynthesis as a potential mechanism. Hum Mol Genet, 2009; 18:4770–4780.

12.

Komaromy

, Alexander

, Rowlan

, et al. Gene therapy rescues cone function in congenital achromatopsia. Hum Mol Genet, 2010; 19:2581–2593.

13.

Carvalho

, Xu

, Pearson

, et al. Long-term and age-dependent restoration of visual function in a mouse model of CNGB3-associated achromatopsia following gene therapy. Hum Mol Genet, 2011; 20:3161–3175.

14.

, Budzynski

, Sonnentag

, et al. Cone-specific promoters for gene therapy of achromatopsia and other retinal diseases. Hum Gene Ther, 2016; 27:72–82.

15.

, Budzynski

, Sonnentag

, et al. Safety and biodistribution evaluation in cynomolgus macaques of rAAV2tYF-PR1.7-hCNGB3, a recombinant AAV vector for treatment of achromatopsia. Hum Gene Ther, 2016; 27 (this issue).

16.

Thomas

, Wang

, Niamke

, et al. Scalable recombinant adeno-associated virus production using recombinant herpes simplex virus type 1 coinfection of suspension-adapted mammalian cells. Hum Gene Ther, 2009; 20:861–870.

17.

Pang

, Chang

, Kumar

, et al. Gene therapy restores vision-dependent behavior as well as retinal structure and function in a mouse model of RPE65 Leber congenital amaurosis. Mol Ther, 2006; 13:565–572.

18.

Lin

, Calcedo

, Vandenberghe

, et al. Impact of preexisting vector immunity on the efficacy of adeno-associated virus-based HIV-1 Gag vaccines. Hum Gene Ther, 2008; 19:663–669.

19.

AGTC. Safety and efficacy of rAAV2tYF-PR1.7-hCNGB3 in patients with achromatopsia. www.clinicaltrials.gov/ct2/show/NCT02599922

20.

, Conlon

, Erger

, et al. Safety and biodistribution evaluation of rAAV2tYF-CB-hRS1, a recombinant adeno-associated virus vector expressing retinoschisin, in RS1-deficient mice. Hum Gene Ther Clin Dev, 2015; 26:177–184.

21.

, Miller

, Han

, et al. Intraocular route of AAV2 vector administration defines humoral immune response and therapeutic potential. Mol Vis, 2008; 14:1760–1769.